Infectious Diseases-L.E.A.P.S.(TM)

L.E.A.P.S.(TM)** (Ligand Epitope Antigen Presentation System) is a patented, T-cell modulation, peptide epitope delivery technology that enables CEL-SCI to design and synthesize proprietary peptide immunogens. L.E.A.P.S.(TM) compounds consist of a small T-cell binding peptide ligand linked with a disease-associated peptide antigen.

This technology has been shown in several animal models to preferentially direct immune response to a cellular (e.g. T-cell), humoral (antibody) or mixed pathway. Diseases for which antigenic epitope sequences have been identified, such as: some infectious diseases, cancer, autoimmune diseases, allergic asthma and allergy, and select CNS diseases (e.g., Alzheimer's) are potential candidates for development using this technology platform. More...

  o Introduction and overview  
  o Summary of L.E.A.P.S.(TM) and CEL-1000 Collaborators  
  o L.E.A.P.S.(TM) Scientific Backgrounder  
  o Background on CEL-1000  


No L.E.A.P.S. product has been approved for sale, barter or exchange by the FDA or any other regulatory agency for any use to treat disease in animals or humans. The safety or efficacy of these products has not been established for any use. Lastly, no definitive conclusions can be drawn from these early-phase, preclinical-trials data involving these investigational products.

** L.E.A.P.S. is the trademark of CEL-SCI for this investigational platform technology, and this proprietary name is subject to FDA review.